syriQ BioPure from Schott Pharma - prefillable syringe tuned for sensitive biologics

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-30, 06:22. Details in the imprint.

The syriQ BioPure prefillable syringe from Schott Pharma lands in the hand like a familiar disposable syringe, but it hides a finely tuned glass and coating concept built for sensitive biologic drugs. You see a clean barrel, a smooth plunger motion and no flashy colors, just a quiet focus on stability.

What syriQ BioPure aims to solve

Schott Pharma designed syriQ BioPure for liquid biologic medicines that can be damaged by trace impurities, rough surfaces or high silicone levels in conventional syringes. The idea is simple: reduce interaction points so proteins stay stable from filling line to patient.

In everyday hospital use that matters, because nurses and pharmacists increasingly handle monoclonal antibodies and other high-value biologics in ready-to-use formats instead of vials and separate syringes. A snagging plunger or visible particles in the barrel are more than annoyances; they can delay treatment or force a discard.

How the syringe is built

syriQ BioPure is a prefillable glass syringe platform with an optimized inner surface, tightly controlled tungsten residue and a carefully managed silicone oil level on the barrel and plunger. The goal is a robust glide force without excess silicone droplets that could interact with the drug formulation.

The system is offered in standard volumes such as 1.0 ml long and 2.25 ml, allowing fill-finish lines already qualified for conventional syringes to handle syriQ BioPure with minor adjustments rather than a complete rebuild. That reduces changeover costs for contract manufacturers.

Focus on biologic stability

For biologic therapies, a syringe is not just a container but part of the formulation environment. If the inner surface sheds ions, tungsten or silicone droplets, proteins can aggregate or form particles that show up as visible specks when a nurse holds the syringe against the light.

Schott Pharma’s engineers therefore worked on tightening glass composition and process controls, aiming to cut extractables that might destabilize fragile molecules. That expertise builds on decades of neutral glass development for vials and ampoules, now transferred to syringes.

How it feels at the bedside

Talk to a hospital pharmacist and you’ll often hear a simple wish: syringes that both fill and inject with consistent force. With syriQ BioPure, the plunger is designed to move with a steady, quiet resistance rather than the jerky start-stop motion you sometimes feel in cheaper systems.

That matters when a biologic infusion starts with a bolus injection at the ward. A smooth plunger helps the nurse deliver the dose at a controlled pace, without sudden jumps that patients can feel as sharp pressure.

Regulatory and quality considerations

Prefillable syringes used for biologics face strict scrutiny from regulators and pharma quality teams. They have to demonstrate low particulate levels, controlled extractables and leachables, and compatibility over long storage times at refrigerated conditions.

syriQ BioPure is positioned as meeting these demands for standard biologic applications, which can shorten risk assessments for drug makers selecting a container system. It does not eliminate formulation work, but it reduces one variable in a complex stability equation.

Integration into fill-finish lines

On the manufacturing side, production managers want syringes that run on high-speed lines with minimal rejects. The dimensions and tolerances of syriQ BioPure are designed to match existing nests and tubs, enabling plug-in use on typical syringe filling equipment.

For contract development and manufacturing organizations, that means they can offer biologic syringe formats without overhauling hardware, which can be a persuasive argument in tender negotiations with biotech clients.

Who Schott Pharma targets

syriQ BioPure is not aimed at individual patients or pharmacies but at pharmaceutical manufacturers, biotech companies and CDMOs that need reliable primary packaging for their biologic portfolios. It is a B2B product that later shows up indirectly in hospitals and clinics.

For those customers, the pitch is about lowering total cost of ownership: fewer stability issues, fewer recalls and a smoother path through regulatory inspections. Schott Pharma tries to back that up with data from mechanical and chemical stress testing.

Voices from the company

In presentations, executives such as CEO Andreas Reisse have framed Schott Pharma as a partner for injectable medicines rather than a simple glass supplier. Their message: as biologics grow, container systems must evolve in lockstep.

Product managers close to syriQ BioPure highlight that development involved collaboration with selected pharma partners, who tested prototypes on real lines and fed back data on particle counts, glide forces and rejection rates during qualification batches.

Strengths and trade-offs

The strengths of syriQ BioPure lie in its alignment with biologic needs: controlled surface chemistry, standard formats and a focus on low particulate load. For many drugs that may be sufficient to make the syringe a safe choice.

The trade-off is that more specialized biologics or high-concentration formulations might still need custom solutions beyond the standard BioPure offering, forcing pharma companies to balance simplicity against bespoke engineering.

Market context and competition

Prefillable syringes for biologics form a competitive niche within pharmaceutical packaging, with several global players pushing their own platforms. Schott Pharma uses syriQ BioPure as one of its answers to that pressure.

As more injectable therapies move from hospital to home, demand for reliable, patient-friendly syringe and autoinjector systems is expected to increase. That gives container suppliers with proven biologic solutions a consistent growth opportunity.

Stock and company context

Schott Pharma, listed in Frankfurt with ISIN DE000A3ENQ51, positions syriQ BioPure as part of its high-value portfolio for injectable medicines. The Schott Pharma share price is driven less by single products than by the overall growth in biologics and injectable therapies, with syriQ BioPure contributing to that narrative.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | DE000A3ENQ51 | SCHOTT PHARMA | boerse | 69656943 | bgmi